Search
Acute Myeloid Leukemia
The AML SWG represents a group of national and internationally renowned clinical and research experts working in the field of AML.
Read moreEHA Diagnosis - Coming in 2024
EHA Diagnosis is a new digital tool that EHA has created exclusively for our members.
Read moreCommonalities and Differences in Myeloid Malignancies: Insights from the EHA-SWG Scientific Meeting on MDS, MPN, and AML
November 2-4 - Budapest, Hungary
Meeting Chairs:
Konstanze Döhner, University Hospital Ulm, Germany
Claire Harrison, Guy's and St.
EHA response to the EU’s Pharma Revision
Last week, the European Affairs team finalised EHA's response to the proposed revision of the EU (European Union) Pharmaceutical Legislation. In April 2023, the European Commission published a proposed Directive and Regulation to replace the current, outdated legal framework.
Read moreEHA Congratulates EHA Research Grants 2022 Recipients
The Hague, May 30, 2022 – EHA congratulates eight talented researchers in hematology on their receipt of the EHA Research Grants 2022 after a rigorous selection process.
Read moreFaculty information
We are honored that you have agreed to be part of the faculty for the EHA Research Conference "Transcriptional control and chromatin alterations in normal and abnormal hematopoiesis", scheduled to take place in Málaga, Spain, on March 17-20, 2025.
Read moreParliament puts final stamp on the European Health Data Space
On April 24, the European Parliament gave its final endorsement to the regulation on the European Health Data Space (EHDS). The legislation was proposed in May 2022, and constitutes an important pillar of the (developing) European Health Union.
Read morePolicy & advocacy
At the core of EHA’s advocacy efforts are four priority themes. For each of these themes, the main messages and recommendations directed at EU institutions and other stakeholders have been written down in a Position Paper.
Read moreNew HemaSphere publication on IVDR implementation
The In Vitro Diagnostic medical devices Regulation (IVDR), which came in to force in May 2022 with the objective of safeguarding the quality and safety of diagnostic tests in the EU, has a major impact on commercially available IVDs (CEIVDs) and…
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- »